Modulation of the cardioprotective effect of ischemic preconditioning in hyperlipidaemic rat heart

European Journal of Pharmacology

Volumn 643, Issue 1, 2010, Pages 78-83

  Yadav, Harlokesh Narayan ^a   Singh, Manjeet ^a   Sharma, Pyare Lal ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Glycogen Synthase Kinase 3 ; Hyperlipidaemia; Ischemic Preconditioning; Mitochondrial Permeability Transition Pore

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; CREATINE KINASE MB; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; INDIRUBIN 3 MONOOXIME; LACTATE DEHYDROGENASE; LITHIUM CHLORIDE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; TRIPHENYLTETRAZOLIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME RELEASE; FEMALE; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PERFUSION; HEART PROTECTION; HYPERLIPIDEMIA; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; ISCHEMIC PRECONDITIONING; ISOLATED HEART; LIPID DIET; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

EID: 77955051502     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.06.015     Document Type: Article

References (69)

1. Abete P., Ferrara N., Cioppa A., Ferrara P., Bianco S., Calabrese C., Cacciatore F., Longobardi G., Rengo F. Preconditioning does not prevent postischemic dysfunction in aging heart. J. Am. Coll. Cardiol. 1996, 27:1777-1786.
2. Antman E.M., Braunwald E. Acute myocardial infarction. Heart Disease, a Textbook of Cardiovascular Medicine 1997, 1184-1188. WB Saunders & Co, Philadelphia. 5th Edn. E. Braunwald (Ed.).
3. Baxter G.F., Ebrahim Z. Role of bradykinin in preconditioning and protection of the ischemic myocardium. Br. J. Pharmacol. 2002, 135:843-854.
4. Bouchard J.F., Chouinard J., Lamontagne D. Role of kinins in the endothelial protective effect of ischaemic preconditioning. Br. J. Pharmacol. 1998, 123:413-420.
5. Chopra K., Singh M., Kaul N., Andrabi K.J., Ganguly N.K. Decrease of myocardial infarct size with desferrioxamine: Possible role of oxygen free radicals in its ameliorative effect. Mol. Cell. Biochem. 1992, 113:71-76.
6. Crompton M., Costi A. Kinetic evidence for a heart mitochondrial pore activated by Ca 2+, inorganic phosphate and oxidative stress. a potential mechanism for mitochondrial dysfunction during cellular Ca 2+ overload. Eur. J. Biochem. 1988, 178:489-501.
7. Defily D.V., Chilian W.M. Preconditioning protects coronary arteriolar endothelium from ischemia-reperfusion injury. Am. J. Physiol. 1993, 265:H700-H706.
8. Del Valle H.F., Lascano E.C., Negroni J.A. Ischaemic preconditioning protection against stunning in conscious diabetic sheep: role of glucose, insulin, sarcolemmal and mitochondrial K ATP channels. Cardiovasc. Res. 2002, 55:642-659.
9. Del Valle H.F., Lascano E.C., Negroni J.A., Crottogini A.J. Absence of ischemic preconditioning protection in diabetic sheep hearts: role of sarcolemmal KATP Channel Dysfunction. Mol. Cell. Biochem. 2003, 249:21-30.
10. Di Lisa F., Bernardi P. Mitochondrial function and myocardial aging. A critical analysis of the role of permeability transition. Cardiovasc. Res. 2005, 66:222-232.
11. Ferdinandy P. Myocardial ischaemia/reperfusion injury and preconditioning: Effects of hypercholesterolaemia/hyperlipidaemia. Br. J. Pharmacol. 2003, 138:283-285.
12. Ferdinandy P., Szilvassy Z., Horvath L.I., Csont T., Csonka C., Nagy E., Szentgyörgyi R., Nagy I., Koltai M., Dux L. Loss of Pacing-induced preconditioning in rat hearts: Role of nitric oxide and cholesterol-enriched diet. J. Mol. Cell. Cardiol. 1997, 29:3321-3333.
13. Ferdinandy P., Szilvassy Z., Baxter G.F. Adaptation to myocardial stress in disease states: Is preconditioning a healthy heart phenomenon?. Trends Pharmacol. Sci. 1998, 19:223-229.
14. Fishbein M.C., Meerbaum S., Rit J., Lando U., Kanmatsuse K., Merair J.C., Corday E., Ganz W. Early phase acute myocardial infarct size quantification: Validation of the triphenyltetrazolium chloride tissue enzyme staining technique. Am. Heart J. 1981, 101:593-600.
15. Forster K., Paul I., Solenkova N., Staudt A., Cohen M.V., Downey J.M., Felix S.B., Kreig T. NECA at reperfusion limits infarction and inhibits formation of the mitochondrial permeability transition pore by activating P70s6 kinase. Basic Res. Cardiol. 2006, 101:319-326.
16. Fryer R.M., Pratt P.F., Hsu A.K., Gross G.J. Differential activation of extracellular signal regulated kinase isoforms in preconditioning and opioid- induced cardioprotection. J. Pharmacol. Exp. Ther. 2001, 296:642-649.
17. Gilde A.J., Van Bilsen M. Peroxisome proliferator-activated receptors (Ppars): Regulators of gene expression in heart and skeletal muscle. Acta Physiol. Scand. 2003, 178:425-434.
18. Giricz Z., Lalu M.M., Csonka C., Bencsik P., Schulz R., Ferdinandy P. Hyperlipidemia attenuates the infarct size-limiting effect of ischemic preconditioning: Role of matrix metalloproteinase-2 inhibition. J. Pharmacol. Exp. Ther. 2006, 316:154-161.
19. Griffiths E.J., Halestrap A.P. Protection by cyclosporin a of ischemia reperfusion- induced damage in isolated rat hearts. J. Mol. Cell. Cardiol. 1993, 25:1461-1469.
20. Griffiths E.J., Halestrap A.P. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem. J. 1995, 307:93-98.
21. Gross E.R., Hsu A.K., Gross G.J. Opioid-induced cardioprotection occurs via glycogen synthase kinase inhibition during reperfusion in intact rat hearts. Circ. Res. 2004, 94:960-966.
22. Halestrap A.P., Clarke S.J., Javadov S.A. Mitochondrial permeability transition pore opening during myocardial reperfusion: a target for cardioprotection. Cardiovasc. Res. 2004, 61:372-385.
23. Hausenloy D.J., Yellon D.M. Preconditioning and Postconditioning: United at reperfusion. Pharmacol. Ther. 2007, 116:173-191.
24. Hausenloy D.J., Maddock H.L., Baxter G.F., Yellon D.M. Inhibiting mitochondrial permeability transition pore opening: A new paradigm for myocardial preconditioning?. Cardiovasc. Res. 2002, 55:534-543.
25. Hausenloy D.J., Duchen M.R., Yellon D.M. Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischemia-reperfusion injury. Cardiovasc. Res. 2003, 60:617-625.
26. Iliodromitis K.E., Lazou A., Kremastinos D.T. Ischemic preconditioning: Protection against myocardial necrosis and apoptosis. Vasc. Health Risk Manag. 2007, 3:629-637.
27. Issemann I., Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347:645-650.
28. Javadov S.A., Clarke S., Das M., Griffiths E.J., Lim K.H., Halestrap A.P. Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart. J. Physiol. 2003, 549:513-524.
29. Juhaszova M., Zorov D.B., Kim S.H., Pepe S., Fu Q., Fishbein K.W., Ziman B.D., Wang S., Ytrehus K., Antos C.L., Olson E.N., Sollott S.J. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J. Clin. Invest. 2004, 113:1535-1549.
30. + exchange inhibitor on cardioprotective effect of ischemic preconditioning: Possible involvement of resident cardiac mast cells. Pharmacol. Res. 1997, 36:95-102.
31. Kocic I., Konstanski Z., Kaminski M., Dworakowska D., Dworakowski R. Experimental hyperlipidemia prevents the protective effect of ischemic preconditioning on the contractility and responsiveness to phenylephrine of rat- isolated stunned papillary muscle. Gen. Pharmacol. 1999, 33:213-219.
32. Langendorff O. Untersuchungen am uberlebender saugethierherzen. Arch. Physiol. 1895, 61:291-332.
33. Leone T.C., Weinheimer C.J., Kelly D.P. A critical role for the peroxisome proliferator-activated receptor alpha (PPAR alpha) in the cellular fasting response: The PPAR alpha-null mouse as a model of fatty acid oxidation disorders. Proc. Natl Acad. Sci. USA 1996, 96:7473-7478.
34. Li R., Zheng W., Pi R., Gao J., Zhang H., Le P.W.K., Liu P. Activation of peroxisome proliferator-activated receptor-a prevents glycogen synthase 3b phosphorylation and inhibits cardiac hypertrophy. FEBS Lett. 2007, 581:3311-3316.
35. Lindell S.L., Klahn S.L., Piazza T.M., Mangino M.J., Torrealba J.R., Southard J.H., Carey H.V. Natural resistance to liver cold ischemia-reperfusion injury associated with the hibernation phenotype. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 288:G473-G480.
36. Liu P., Xu B., Cavalieri T.A., Hock C.E. Attenuation of antioxidative capacity enhances reperfusion-injury in aged rat myocardium following MI/R. Am. J. Physiol. Heart Circ. Physiol. 2004, 287:H2719-H2727.
37. Lorkowska B., Bartus M., Franczyk M., Kostogrys R.B., Jawien J., Pisulewski P.M., Chlopicki S. Hypercholesterolemia does not alter endothelial function in spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 2006, 317:1019-1026.
38. Mejía-Vilet J.M., Ramírez V., Cruz C., Uribe N., Gamba G., Bobadilla N.A. Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone. Am. J. Physiol. Ren. Physiol. 2007, 293:78-86.
39. Murray C.J., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study. Lancet 1997, 349:1498-1504.
40. Murry C.E., Jennings R.B., Reimer K.A. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986, 74:1124-1136.
41. Nakamura M., Wang N.P., Zhao Z.Q., Wilcox J.N., Thourani V., Guyton R.A., Vinten- Johansen J. Preconditioning decreases bax expression, PMN accumulation and apoptosis in reperfused rat heart. Cardiovasc. Res. 2000, 45:661-670.
42. Neaton J.D., Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316099 white men. Multiple risk factor intervention trial research group. Arch. Intern. Med. 1992, 152:56-64.
43. Nieszner E., Posa I., Kocsis E., Pogatsa G., Preda I., Koltai M.Z. Influence of diabetic state and that of different sulfonylureas on the size of myocardial infarction with and without ischemic preconditioning in rabbits. Exp. Clin. Endocrinol. Diab. 2002, 110:212-218.
44. Nishihara M., Miura T., Miki T., Sakamoto J., Tanno M., Kobayashi H., Ikeda Y., Ohori K., Takahashi A., Shimamoto K. Erythropoietin affords additional cardioprotection to preconditioned hearts by enhanced phosphorylation of glycogen synthase kinase-3β. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H748-H755.
45. Nishihara M., Miura T., Miki T., Tanno M., Yano T., Naitoh K., Ohori K., Hotta H., Terashima Y., Shimamoto K. Modulation of the mitochondrial permeability transition pore complex in GSK-3beta-mediated myocardial protection. J. Mol. Cell. Cardiol. 2007, 43:564-570.
46. Oldenburg O., Qin Q., Sharma A.R., Cohen M.V., Downey J.M., Benoit J.N. Acetylcholine leads to free radical production dependent on KATP channels, G I proteins, phosphatidylinositol 3-kinase and tyrosine kinase. Cardiovasc. Res. 2002, 55:544-552.
47. Oudit G.Y., Sun H., Kerfant B.G., Crackower M.A., Penninger J.M., Backx P.H. the role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J. Mol. Cell. Cardiol. 2004, 37:449-471.
48. Parikh V., Singh M. Resident cardiac mast cells and the cardioprotective effect of ischemic preconditioning in isolated rat heart. J. Cardiovasc. Pharmacol. 1997, 30:149-156.
49. Parikh V., Singh M. Possible role of adrenergic component and cardiac mast cell degranulation in preconditioning induced cardioprotection. Pharmacol. Res. 1999, 40:129-137.
50. Park S.S., Zhao H., Jang Y., Mueller R.A., Xu Z. N6-(3-Iodobenzyl)-adenosine- 5'-N methylcarboxamide confers cardioprotection at reperfusion by inhibiting mitochondrial permeability transition pore opening via glycogen synthase kinase-3 beta. J. Pharmacol. Exp. Ther. 2006, 318:124-131.
51. Park S.S., Zhao H., Mueller R., Xu Z. Bradykinin prevents reperfusion injury by targeting mitochondrial permeability transition pore through glycogen synthase kinase 3β. J. Mol. Cell. Cardiol. 2006, 40:708-716.
52. Pearce N.J., Arch J.R., Clapham J.C., Coghlan M.P., Corcoran S.L., Lister C.A., Llano A., Moore G.B., Murphy G.J., Smith S.A., Taylor C.M., Yates J.W., Morrison A.D., Haper A.J., Roxbee-Cox L., Abuin A., Wargent E., Holder J.C. Development of glucose intolerance in male transgenic mice overexpressing human glycogen synthase kinase-3beta on a muscle-specific promoter. Metabolism 2004, 53:1322-1330.
53. Piper H.M., Abdallah Y., Schäfer C. The first minutes of reperfusion: A window of opportunity for cardioprotection. Cardiovasc. Res. 2004, 61:365-367.
54. Reeves P.G. Components of the AIN-93 diets as improvements in the AIN-76a diet. J. Nutr. 1997, 127:838S-841S.
55. Sasaki H., Ogawa K., Shimizu M., Mori C., Takatsuka H., Okazaki F., Kawai M., Taniguchi I., Mochizuki S. The insulin sensitizer pioglitazone improves the deterioration of ischemic preconditioning in Type 2 diabetes mellitus rats int. Heart J. 2007, 48:623-635.
56. Singh M., Sharma A. Mechanism of cardioprotective effect of remote aortic preconditioning. Pathophysiology of cardiovascular diseases 2004, 277-285. Kluwer Academic Publishers, Boston. N.S. Dhalla, R.A. Angel, G.N. Pierce (Eds.).
57. Snoeckx L.H., Van Der, Vusse G.J., Coumans W.A., Willemsen P.H.M., Van Der, Nagel T., Reneman R.S. Myocardial function in normal and spontaneously hypertensive rats during reperfusion after a period of global ischemia. Cardiovasc. Res. 1986, 20:67-75.
58. Snoeckx L.H., Van Der, Vuesse G.J., Coumans W.A., Willemsen P.H., Reneman R.S. Differences in ischaemia tolerance between hypertrophied hearts of adult and aged spontaneously hypertensive rats. Cardiovasc. Res. 1993, 27:874-881.
59. Szilvassy Z., Ferdinandy P., Szilvassy J., Nagy I., Karcsu S., Lonovics J., Dux L., Koltai M. The Loss of pacing-induced preconditioning in atherosclerotic rabbits: role of hypercholesterolemia. J. Mol. Cell. Cardiol. 1995, 27:2559-2569.
60. Tong H., Chen W., Steenbergen C., Murphy E. Ischemic preconditioning activates phosphatidylinositol-3-Kinase upstream of protein kinase c. Circ. Res. 2000, 87:309-315.
61. Tong H., Imahashi K., Steenbergen C., Murphy E. Phosphorylation of glycogen synthase kinase-3beta during preconditioning through a phosphatidylinositol-3- kinase-dependent pathway is cardioprotective. Circ. Res. 2002, 90:377-379.
62. Topol E.J., Califf R.M., Vandormael M., Grines C.L., George B.S., Sanz M.L., Wall T., O'Brien M., Schwaiger M., Aguirre F.V., Young S., Popma J.J., Sigmon K.N., Lee K.L., Ellis S.G. The thrombolysis and angioplasty in myocardial infarction, a randomized trial of late reperfusion therapy for acute myocardial infarction. Circulation 1992, 85:2090-2099.
63. Tsang A., Hausenloy D.J., Mocanu M.M., Yellon D.M. Postconditioning: a form of "Modified Reperfusion" protects the myocardium by activating the Phosphatidylinositol 3-Kinase-Akt Pathway. Circ. Res. 2004, 95:230-232.
64. Tsang A., Hausenloy D.J., Yellon D.M. Myocardial postconditioning: reperfusion injury revisited. Am. J. Physiol. Heart Circ. Physiol. 2005, 289:H2-H7.
65. Ueda Y., Kitakaze M., Komamura K., Minamino T., Asanuma H., Sato H., Kuzuya T., Takeda H., Hori M. Pravastatin restored the infarct size limiting effect of ischemic preconditioning blunted by hypercholesterolemia in the rabbit model of myocardial infarction. J. Am. Coll. Cardiol. 1999, 34:2120-2125.
66. Ungi I., Ungi T., Ruzsa Z., Nagy E., Zimmermann Z., Csont T., Ferdinandy P. Hypercholesterolemia attenuates the anti-ischemic effect of preconditioning during coronary angioplasty. Chest 2005, 128:1623-1628.
67. 2+ during ischemia in rat hearts: Role of KATP channels. Am. J. Physiol. Heart Circ. Physiol. 2001, 280:H2321-H2328.
68. Wilson P.W. Established risk factors and coronary artery disease: The framingham study. Am. J. Hypertens. 1994, 7:7S-12S.
69. Xi J., Wang H., Mueller R.A., Norfleet E.A., Xu Z. Mechanism for resveratrol- induced cardioprotection against reperfusion injury involves glycogen synthase kinase 3beta and mitochondrial permeability transition pore. Eur. J. Pharmacol. 2009, 604:111-116.